You just read:

IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

News provided by

Janssen Biotech, Inc.

Feb 12, 2014, 01:37 ET